MCID: PRC016
MIFTS: 63

Pre-Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pre-Eclampsia

MalaCards integrated aliases for Pre-Eclampsia:

Name: Pre-Eclampsia 12 25 43 15 71
Preeclampsia 12 74 25 58 29 54 6 17
Hypertension, Pregnancy-Induced, Susceptibility to 29 6
Pregnancy Associated Hypertension 12 71
Gestational Hypertension 12 15
Proteinuric Hypertension of Pregnancy 12
Gestational Proteinuric Hypertension 25
Transient Hypertension of Pregnancy 71
Hypertension Induced by Pregnancy 12
Preeclampsia, Susceptibility to 6
Pregnancy-Induced Hypertension 25
Pre-Eclamptic Toxaemia 12
Preeclampsia/eclampsia 12
Toxaemia of Pregnancy 12
Toxemia of Pregnancy 25
Pregnancy Toxemia 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:10591
MeSH 43 D011225
NCIt 49 C85021
SNOMED-CT 67 398254007
ICD10 32 O13 O14 O14.9
ICD10 via Orphanet 33 O14.0 O14.1 O14.2 more
UMLS via Orphanet 72 C0032914
Orphanet 58 ORPHA275555
UMLS 71 C0032914 C0341934 C0852036

Summaries for Pre-Eclampsia

Genetics Home Reference : 25 Preeclampsia is a complication of pregnancy in which affected women develop high blood pressure (hypertension); they can also have abnormally high levels of protein in their urine (proteinuria). This condition usually occurs in the last few months of pregnancy and often requires early delivery of the infant. However, this condition can also appear shortly after giving birth (postpartum preeclampsia). Many women with mild preeclampsia do not feel ill, and the condition is often first detected through blood pressure and urine testing in their doctor's office. In addition to hypertension and proteinuria, signs and symptoms of preeclampsia can include excessive swelling (edema) of the face or hands and a weight gain of more than 3 to 5 pounds in a week due to fluid retention. Affected women may also experience headaches, dizziness, irritability, shortness of breath, a decrease in urination, upper abdominal pain, and nausea or vomiting. Vision changes may develop, including flashing lights or spots, increased sensitivity to light (photophobia), blurry vision, or temporary blindness. In many cases, symptoms of preeclampsia go away within a few days after the baby is born. In severe cases, however, preeclampsia can damage the mother's organs, such as the heart, liver, and kidneys, and can lead to life-threatening complications. Extremely high blood pressure in the mother can cause bleeding in the brain (hemorrhagic stroke). The effects of high blood pressure on the brain (hypertensive encephalopathy) may also result in seizures. If seizures occur, the condition is considered to have worsened to eclampsia, which can result in coma. About 1 in 200 women with untreated preeclampsia develop eclampsia. Eclampsia can also develop without any obvious signs of preeclampsia. Between 10 and 20 percent of women with severe preeclampsia develop another potentially life-threatening complication called HELLP syndrome. HELLP stands for hemolysis (premature red blood cell breakdown), elevated liver enzyme levels, and low platelets (cells involved in blood clotting), which are the key features of this condition. Severe preeclampsia can also affect the fetus, with impairment of blood and oxygen flow leading to growth problems or stillbirth. Infants delivered early due to preeclampsia may have complications associated with prematurity, such as breathing problems caused by underdeveloped lungs. Women who have had preeclampsia have approximately twice the lifetime risk of heart disease and stroke than do women in the general population. Researchers suggest that preeclampsia, heart disease, and stroke may share common risk factors. Women who have health conditions such as obesity, hypertension, heart disease, diabetes, or kidney disease before they become pregnant have an increased risk of developing preeclampsia. Preeclampsia is most likely to occur in a woman's first pregnancy, although it can occur in subsequent pregnancies, particularly in women with other health conditions.

MalaCards based summary : Pre-Eclampsia, also known as preeclampsia, is related to mild pre-eclampsia and eclampsia, and has symptoms including edema, hyperemesis gravidarum and morning sickness. An important gene associated with Pre-Eclampsia is NSD1 (Nuclear Receptor Binding SET Domain Protein 1), and among its related pathways/superpathways is VEGF binds to VEGFR leading to receptor dimerization. The drugs Magnesium oxide and Granisetron have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and liver, and related phenotypes are proteinuria and hypertension

Disease Ontology : 12 A hypertension occurring during pregnancy characterized by large amounts of protein in the urine (proteinuria) and edema, usually by the last trimester of pregnancy.

Wikipedia : 74 Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and... more...

Related Diseases for Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 741)
# Related Disease Score Top Affiliating Genes
1 mild pre-eclampsia 35.8 PGF PAPPA FLT1 ENG
2 eclampsia 35.0 TAC3 STOX1 PGF PEE1 PAPPA FLT1
3 hellp syndrome 34.0 PGF FLT1 ENG
4 placental abruption 32.6 PGF PAPPA FLT1 ENG
5 placenta disease 32.4 PGF PAPPA FLT1
6 placental insufficiency 32.1 PGF PAPPA FLT1
7 placenta praevia 31.5 PGF PAPPA
8 ectopic pregnancy 31.2 PGF PAPPA FLT1
9 placenta accreta 31.1 PGF PAPPA FLT1
10 twin-to-twin transfusion syndrome 31.0 PGF PAPPA FLT1 ENG
11 pulmonary hypertension, primary, 1 30.1 MALAT1 ENG
12 renal cell carcinoma, nonpapillary 29.7 TUG1 SPRY4-IT1 PGF MALAT1 HOTAIR H19
13 osteogenic sarcoma 29.5 TUG1 MALAT1 HOTAIR H19
14 lung cancer susceptibility 3 29.1 TUG1 MALAT1 HOTAIR H19 FLT1
15 severe pre-eclampsia 13.2
16 preeclampsia/eclampsia 3 12.4
17 preeclampsia/eclampsia 4 12.3
18 preeclampsia/eclampsia 5 12.3
19 preeclampsia/eclampsia 1 11.9
20 gestational diabetes 11.8
21 alpha-thalassemia 11.5
22 trichothiodystrophy 11.5
23 factor v leiden thrombophilia 11.2
24 neonatal anemia 10.9 PGF PAPPA FLT1 ENG
25 glomeruloid hemangioma 10.8 FLT1 ENG
26 cancer-associated retinopathy 10.8 PGF FLT1
27 epithelioid hemangioendothelioma 10.8 PGF FLT1
28 hypertension, essential 10.7
29 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.6
30 disseminated intravascular coagulation 10.6
31 yemenite deaf-blind hypopigmentation syndrome 10.6
32 thrombocytopenia 10.6
33 thrombophilia 10.6
34 kuhnt-junius degeneration 10.6 PGF FLT1
35 body mass index quantitative trait locus 1 10.6
36 antiphospholipid syndrome 10.6
37 kidney disease 10.5
38 acute kidney failure 10.5
39 chronic kidney disease 10.5
40 retinal detachment 10.5
41 pulmonary edema 10.5
42 vascular disease 10.5
43 autoimmune disease 10.5
44 cortical blindness 10.5
45 neovascular glaucoma 10.5 PGF FLT1
46 wilms tumor predisposition 10.4 NSD1 H19
47 nephrotic syndrome 10.4
48 hypothyroidism 10.4
49 postpartum psychosis 10.4
50 hydatidiform mole, recurrent, 1 10.4

Graphical network of the top 20 diseases related to Pre-Eclampsia:



Diseases related to Pre-Eclampsia

Symptoms & Phenotypes for Pre-Eclampsia

Human phenotypes related to Pre-Eclampsia:

58 31 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 proteinuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000093
2 hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0000822
3 abnormality of the placenta 58 31 hallmark (90%) Very frequent (99-80%) HP:0100767
4 elevated systolic blood pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0004421
5 elevated diastolic blood pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0005117
6 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
7 intrauterine growth retardation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001511
8 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
9 abnormality of vision 58 31 occasional (7.5%) Occasional (29-5%) HP:0000504
10 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
11 small for gestational age 58 31 occasional (7.5%) Occasional (29-5%) HP:0001518
12 abnormality of the hepatic vasculature 58 31 occasional (7.5%) Occasional (29-5%) HP:0006707
13 increased body mass index 58 31 occasional (7.5%) Occasional (29-5%) HP:0031418
14 sleep disturbance 58 31 very rare (1%) Very rare (<4-1%) HP:0002360
15 type i diabetes mellitus 58 31 very rare (1%) Very rare (<4-1%) HP:0100651
16 autoimmunity 58 31 very rare (1%) Very rare (<4-1%) HP:0002960
17 thrombocytopenia 58 31 very rare (1%) Very rare (<4-1%) HP:0001873
18 polycystic ovaries 58 31 very rare (1%) Very rare (<4-1%) HP:0000147
19 chronic kidney disease 58 31 very rare (1%) Very rare (<4-1%) HP:0012622
20 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
21 elevated serum creatinine 58 31 very rare (1%) Very rare (<4-1%) HP:0003259
22 helicobacter pylori infection 58 31 very rare (1%) Very rare (<4-1%) HP:0005202
23 abnormality of the kidney 58 Occasional (29-5%)
24 abnormality of the nervous system 58 Occasional (29-5%)

UMLS symptoms related to Pre-Eclampsia:


edema, hyperemesis gravidarum, morning sickness

Drugs & Therapeutics for Pre-Eclampsia

Drugs for Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 417)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium oxide Approved Phase 4 1309-48-4 14792
2
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Dinoprostone Approved Phase 4 363-24-6 5280360
5
Captopril Approved Phase 4 62571-86-2 44093
6
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
7
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Racepinephrine Approved Phase 4 329-65-7 838
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Amlodipine Approved Phase 4 88150-42-9 2162
12
Halofantrine Approved Phase 4 69756-53-2 37393
13
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Labetalol Approved Phase 4 36894-69-6 3869
16
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
17
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
18
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
19
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
20
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
21
Enalaprilat Approved Phase 4 76420-72-9 6917719
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Azithromycin Approved Phase 4 83905-01-5 447043 55185
24
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
25
Caffeine Approved Phase 4 58-08-2 2519
26
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
27
Ethanol Approved Phase 4 64-17-5 702
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Desogestrel Approved Phase 4 54024-22-5 40973
32
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
33
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
34
Metformin Approved Phase 4 657-24-9 14219 4091
35
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
36
Glyburide Approved Phase 4 10238-21-8 3488
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Ibuprofen Approved Phase 4 15687-27-1 3672
39
Phenylephrine Approved Phase 4 59-42-7 6041
40
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
41 Garlic Approved, Nutraceutical Phase 4 8008-99-9
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
43 Tocotrienol Investigational Phase 4 6829-55-6
44 Tocotrienols Phase 4
45 Tocopherols Phase 4
46 Pharmaceutical Solutions Phase 4
47 Anesthetics, Local Phase 4
48 Dextrans Phase 4
49 Omega 3 Fatty Acid Phase 4
50 Parasympatholytics Phase 4

Interventional clinical trials:

(show top 50) (show all 946)
# Name Status NCT ID Phase Drugs
1 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
2 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
3 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Unknown status NCT03449277 Phase 4 Oral Tablet
4 Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial) Unknown status NCT00117546 Phase 4 alpha methyldopa
5 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
6 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
7 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Unknown status NCT03233880 Phase 4 Azithromycin 1gm
8 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
9 Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy Unknown status NCT03237000 Phase 4 MgSO4
10 Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages Unknown status NCT01718340 Phase 4 Metformin
11 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
12 Improvement of Utero-Placental Perfusion and Fetal Growth in IUGR and PET by Administration of Sildenafil Citrate in Pregnancy Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
13 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
14 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
15 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
16 Study the Effect of Intravenous Hyoscine Butylbromide Injection on the Duration and Progress of First Stage Labour in High Risk Women Unknown status NCT03055390 Phase 4 hyoscine butylbromide;placebo
17 A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
18 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
19 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
20 Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients Completed NCT03506724 Phase 4 Nifedipine;Labetalol
21 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
22 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
23 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
24 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
25 Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
26 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
27 Efficacy and Safety of Hyoscine N Butyl Bromide on the Augmentation of Labor: a Double-Blind, Placebo - Controlled Trial Completed NCT02098889 Phase 4 hyoscine-N-butyl bromide(HBB);Saline
28 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
29 Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women Completed NCT02835339 Phase 4 Magnesium sulfate 4g loading dose, 1g/hr infusion;Magnesium sulfate 6g loading dose, 2g/hr infusion
30 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
31 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
32 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
33 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
34 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
35 Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation Completed NCT02353806 Phase 4 Amlodipine besylate
36 Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy Completed NCT02086838 Phase 4 Theragran Hematinic;low molecular weight iron dextran
37 The Comparison of Hyperbaric Bupivacaine Plus Fentanyl and Hyperbaric Levobupivacaine Plus Fentanyl Administered Intrathecally in Patients Undergoing Elective Cesarean Section Completed NCT02025374 Phase 4 Hyperbaric levobupivacaine;Hyperbaric bupivacaine % 0.5
38 A Prospective Multi-centre Randomised Comparison on Induction of Labour With Double-balloon Installation Device Versus Prostaglandin E2 Minprostin Completed NCT01255839 Phase 4 Minprostin
39 Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
40 Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia Completed NCT02447250 Phase 4 Varied albuterol dose response
41 Effect of Myofascial Release on Electrophysiological and Clinical Measures of Pregnant Women With Carpal Tunnel Syndrome Completed NCT03802448 Phase 4
42 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
43 Outcomes of Epidural Versus Combined Spinal and Epidural (CSE) Anesthetic Technique on the Success of Trial of Labor After Cesarean (TOLAC): A Pilot Study Completed NCT02105558 Phase 4 Epidural anesthesia;Combined spinal and epidural anesthesia
44 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
45 Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
46 Effect of Non-steroidal Anti-inflammatory Use on Blood Pressure in Women With Hypertensive Disorders of Pregnancy: A Randomized Open Label Trial Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
47 Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study Recruiting NCT04077853 Phase 4 17 Hydroxyprogesterone Capronate
48 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Recruiting NCT04392375 Phase 4 Nifedipine 30 MG;Placebos
49 Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial Recruiting NCT04051567 Phase 4 Aspirin 100mg
50 A Randomized Controlled Trial Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Recruiting NCT04236258 Phase 4 NIFEdipine ER;Enalapril

Search NIH Clinical Center for Pre-Eclampsia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Magnesium Sulfate

Cochrane evidence based reviews: pre-eclampsia

Genetic Tests for Pre-Eclampsia

Genetic tests related to Pre-Eclampsia:

# Genetic test Affiliating Genes
1 Preeclampsia 29
2 Hypertension, Pregnancy-Induced, Susceptibility to 29

Anatomical Context for Pre-Eclampsia

MalaCards organs/tissues related to Pre-Eclampsia:

40
Placenta, Endothelial, Liver, Testes, Kidney, Heart, Lung

Publications for Pre-Eclampsia

Articles related to Pre-Eclampsia:

(show top 50) (show all 30606)
# Title Authors PMID Year
1
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 61 54 6
16059745 2005
2
The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption. 6 54 61
11354626 2001
3
Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. 61 6
11745998 2001
4
Angiotensinogen: a candidate gene involved in preeclampsia? 61 6
8348146 1993
5
A molecular variant of angiotensinogen associated with preeclampsia. 61 6
8513325 1993
6
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 6
17165044 2007
7
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 6
16813604 2006
8
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 6
15007011 2004
9
Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. 6
11394896 2001
10
NOS3 polymorphism not associated with Alzheimer's disease in Japanese. 6
11026457 2000
11
A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. 6
10510054 1999
12
Association between Alzheimer's disease and the NOS3 gene. 6
10514107 1999
13
The Glu-298-->Asp (894G-->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. 6
10475066 1999
14
Coronary artery disease is not associated with the E298-->D variant of the constitutive, endothelial nitric oxide synthase gene. 6
9894802 1998
15
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population. 6
9831339 1998
16
A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. 6
9737779 1998
17
Angiotensinogen gene and hypertension in Chinese. 6
9421481 1998
18
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 6
9259580 1997
19
Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. 6
7649545 1995
20
The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. 6
7883995 1995
21
Rapid detection of the hypertension-associated Met235-->Thr allele of the human angiotensinogen gene. 6
8518804 1993
22
Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. 54 61
19916874 2010
23
Soluble endoglin in preeclamptic patients with or without HELLP syndrome. 61 54
20430360 2010
24
Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. 54 61
20206155 2010
25
Nicotine suppresses interleukin-6 production from vascular endothelial cells: a possible therapeutic role of nicotine for preeclampsia. 54 61
20220107 2010
26
The association between preeclampsia and placental disruption induced by chorionic villous sampling. 61 54
20509159 2010
27
Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. 54 61
20502295 2010
28
Circulating angiogenic factors and their association with birth outcomes in preeclampsia. 61 54
20224572 2010
29
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. 61 54
20205159 2010
30
Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. 61 54
19269632 2010
31
Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. 54 61
20237132 2010
32
Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. 61 54
20374043 2010
33
Relation between first trimester maternal serum leptin levels and body mass index in normotensive and pre-eclamptic pregnancies--role of leptin as a marker of pre-eclampsia: a prospective case-control study. 61 54
20050765 2010
34
High levels of human chorionic gonadotropin (hCG) correlate with increased aquaporin-9 (AQP9) expression in explants from human preeclamptic placenta. 61 54
20220109 2010
35
Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. 54 61
20150910 2010
36
Effects of labor on placental expression of superoxide dismutases in preeclampsia. 61 54
20226522 2010
37
Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. 61 54
20131286 2010
38
Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy. 54 61
20303587 2010
39
MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. 61 54
20452491 2010
40
Allelic variations in angiogenic pathway genes are associated with preeclampsia. 61 54
20223440 2010
41
VEGF in the muscular layer of placental blood vessels: immuno-expression in preeclampsia and intrauterine growth restriction and its association with the antioxidant status. 54 61
20184549 2010
42
Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia - New perspectives to explain the pathophysiology. 54 61
20167365 2010
43
Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. 54 61
20002457 2010
44
Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy. 54 61
20070288 2010
45
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. 54 61
20101671 2010
46
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. 54 61
20074261 2010
47
A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. 54 61
20130210 2010
48
Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction. 54 61
20080845 2010
49
Plasma interleukin-18 (IL-18) levels are correlated with antioxidant vitamin coenzyme Q(10) in preeclampsia. 54 61
20199352 2010
50
Association of midgestational paraoxonase 1 activity with pregnancies complicated by preeclampsia. 61 54
19685420 2010